<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01923194</url>
  </required_header>
  <id_info>
    <org_study_id>000055</org_study_id>
    <nct_id>NCT01923194</nct_id>
  </id_info>
  <brief_title>Evaluation of Efficacy and Safety of Highly Purified Urofollitropin for Ovulation Induction in Chinese Females</brief_title>
  <acronym>Compass</acronym>
  <official_title>A Randomized, Assessor-blinded, Parallel Group, Multi-center, Non-inferiority Study Investigating the Efficacy and Safety of Highly Purified Urofollitropin for Injection Compared to Recombinant Human Follitropin Alfa for Injection for Ovulation Induction Using a Low-dose, Step-up Protocol in Chinese Females With WHO Group II Anovulatory Infertility Failing to Conceive on Clomiphene Citrate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ferring Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ferring Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate the Efficacy and Safety of Highly Purified Urofollitropin for Injection Compared to
      Recombinant Human Follitropin Alfa for Injection for Ovulation Induction in Chinese females
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The ovulation rate defined as the percentage of subjects who present ovulation</measure>
    <time_frame>From 6 days up to 7 weeks post hCG (human chorionic gonadotropin) administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The positive serum progesterone rate</measure>
    <time_frame>6~9 days post hCG administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The positive serum β-hCG/hCG rate</measure>
    <time_frame>18~22 days post hCG administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The clinical pregnancy rate</measure>
    <time_frame>6~7 weeks post hCG administration</time_frame>
    <description>Regardless of fetal heart beat</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The clinical pregnancy rate</measure>
    <time_frame>6~7 weeks post hCG administration</time_frame>
    <description>With fetal heart beat</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The ongoing pregnancy rate</measure>
    <time_frame>11~12 weeks post hCG administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The follicular development</measure>
    <time_frame>On the day of hCG administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endometrial thickness</measure>
    <time_frame>On the day of hCG administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total FSH (Follicle-stimulating hormone) dose administered</measure>
    <time_frame>On the day of hCG administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of FSH treatment days</measure>
    <time_frame>On the day of hCG administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency and severity of adverse events</measure>
    <time_frame>Expected maximum of 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency and severity of injection site reactions</measure>
    <time_frame>Day 1 up to Day 28 of the ovarian stimulation period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum estradiol (E2) levels</measure>
    <time_frame>On the day of hCG administration</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">215</enrollment>
  <condition>Anovulation</condition>
  <arm_group>
    <arm_group_label>Test Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Comparator Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Highly Purified Urofollitropin</intervention_name>
    <description>for Injection</description>
    <arm_group_label>Test Group</arm_group_label>
    <other_name>Bravelle®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Recombinant Human Follitropin Alfa</intervention_name>
    <description>for Injection</description>
    <arm_group_label>Comparator Group</arm_group_label>
    <other_name>Gonal-F®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent form prior to screening evaluations

          -  Chinese females between the ages of 20-39 years

          -  Infertility for at least 1 year before screening

          -  Women WHO type II anovulatory infertility with chronic anovulation (defined as
             amenorrhoea (i.e., no menstrual bleeding for 6 months or more) or oligoamenorrhoea
             (i.e., cycles of more than 35 days) ) with progestogen induced withdrawal bleeding or
             spontaneous menstrual bleeding

          -  Failure to conceive after at least one cycle of ovulation induction with clomiphene
             citrate

          -  Bilateral tubal patency documented by a hysterosalpingography or sonohysterography or
             laparoscopy within 2 years prior to screening

          -  Normal pelvis documented by a transvaginal ultrasound with respect to uterus,
             Fallopian tubes and ovaries within 3 months prior to screening

          -  Early follicular phase serum levels of FSH within normal limits (1-12 IU/L,) (results
             obtained within 2 months prior to randomization)

          -  LH (Luteinizing hormone), prolactin , E2 (estradiol), progesteron, total testosterone,
             and TSH (thyrotropin) levels within normal limits for the clinical laboratory

          -  Male partner with a semen analysis obtained within 12 months prior to randomisation
             and showing acceptable values for semen according to the local laboratory, or showing
             more than 2.000.000 progressive motile sperm per mL after capacitation (in case of IUI
             (intrauterine insemination))

          -  BMI (Body mass index) is ≥ 18.5 and &lt; 30 kg/m2

        Exclusion Criteria:

          -  Any known clinically significant systemic disease

          -  Known past or current thrombophlebitis or thromboembolism including venous thrombosis
             disease and active or recent arterial thrombosis disease

          -  Any known endocrine or metabolic abnormalities which can compromise participation in
             the trial with the exception of controlled thyroid function disease

          -  Any known concomitant medications that would interfere with evaluation of study
             medications. Specifically, any non-study hormonal therapy (except for thyroid
             medication), anti-psychotics, anxiolytics, hypnotics and sedatives, and need for
             continuous use of prostaglandin inhibitors (non-steroid anti- inflammatory drugs
             (NSAIDs), including aspirin) at the time of study entry.

          -  Known history of 12 or more unsuccessful (no pregnancy achieved) ovulation induction
             cycles

          -  Any known treatment with clomiphene citrate, metformin, gonadotropins or GnRH
             analogues within one month prior to randomisation

          -  Ovarian cysts with a mean diameter ≥ 15 mm that have persisted for more than one cycle
             or ovarian endometrioma on ultrasound

          -  Known at least one previous cycle experienced luteinized unruptured follicle syndrome

          -  Known abnormal results of cervical examination of clinical significance obtained
             within 1 years prior to screening

          -  Abnormal vaginal bleeding of undetermined origin

          -  Known tumors of the ovary, breast, uterus, adrenal gland, pituitary or hypothalamus

          -  Known malformations of the sexual organs incompatible with pregnancy

          -  Known current or past (last 12 months) abuse of alcohol or drugs

          -  Known history of chemotherapy (except for gestational conditions) or radiotherapy

          -  Finding of any clinically relevant abnormal laboratory value

          -  Use of any non registered investigational drugs during 3 months before screening or
             previous participation in the study

          -  Pregnancy, lactation or contraindication to pregnancy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>39 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Development Support</last_name>
    <role>Study Director</role>
    <affiliation>Ferring Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chinese PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Navy General Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peking University First Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peking University People's Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sun Yat-sen Memorial Hospital Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Third Affiliated Hospital of Guangzhou Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tongji Hospital Tongji Medical College of HUST Tongji Medical College Huazhong University of Science &amp; Technology</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital with Nanjing Medical University</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ShengJing Hospital of China Medical University</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sichuan Provincial People's Hospital</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tianjin Medical University General Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 12, 2013</study_first_submitted>
  <study_first_submitted_qc>August 12, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 15, 2013</study_first_posted>
  <last_update_submitted>August 20, 2015</last_update_submitted>
  <last_update_submitted_qc>August 20, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 21, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anovulation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Follicle Stimulating Hormone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

